Press Release: raises € 44 million in first close of its Series D
Summary
Univercells, a global life science company providing all-round solutions for biologics manufacturing, has raised 44 million through the first close of its Series D financing round. In addition to the support of existing private and public shareholders, Univercells is very pleased to welcome prominent new investors from Belgium and the United States.Univercells has raised 44 million through the first close of its Series D financing round. The initiative was successful beyond expectations and will contribute to the growth of the Group, while reinforcing the engagement of all colleagues.The proceeds will mainly support the development of (i) Quantoom Biosciences RNA platform, complementing funds from the Bill & Melinda Gates Foundation and the Walloon Region (DGO6), (ii) the commercial expansion of Exotheras Jumet-based infrastructure, and (iii) the global growth of the Univercells Group.The Univercells Group is fulfilling its global mission to make biologics available and accessible to all from its home base of Belgium, while continuing to explore paths for international expansion. In the meantime, the arrival of new national and international investors will help strengthen Univercells ambition to achieve the developments it aims for in global health in the coming years. Hugues Bultot, co-founder and CEO of the Univercells Group commented: This first Series D closing is another step towards the realization of our mission to make biologics available to all and to successfully address health challenges during and between pandemics.